Physician profile
Eric Boyum
NPI 1093034266
$3,527.35
in general payments reported to CMS, 2019-2025
20 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $322 · 2021: $62.20 · 2022: $586 · 2023: $731 · 2024: $998 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.92 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $592.18 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $563.82 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $452.97 | 2020-2025 | Caplyta |
| Alkermes, INC. | $449.10 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $244.43 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $218.20 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $213.71 | 2022-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $189.34 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $186.48 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $85.69 | 2022-2023 | Auvelity |
| Sunovion Pharmaceuticals INC. | $66.02 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $57.50 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $40.80 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $37.81 | 2022-2023 | Fanapt, Hetlioz |
| Allergan, INC. | $29.58 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $27.97 | 2023 | Azstarys |
| Amgen INC. | $25.65 | 2019 | |
| Dexcom, INC. | $17.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.95 | 2022 | |
| Neuronetics, INC. | $13.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Boyum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.